162 related articles for article (PubMed ID: 37865101)
1. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):905-914. PubMed ID: 37865101
[TBL] [Abstract][Full Text] [Related]
2. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Respir Med; 2021 Dec; 9(12):1419-1426. PubMed ID: 34672950
[TBL] [Abstract][Full Text] [Related]
3. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Jan; 399(10320):143-151. PubMed ID: 34800427
[TBL] [Abstract][Full Text] [Related]
4. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 Feb; 397(10274):605-612. PubMed ID: 33545096
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2020 Oct; 396(10259):1345-1352. PubMed ID: 33031764
[TBL] [Abstract][Full Text] [Related]
6. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
;
Lancet; 2023 May; 401(10387):1499-1507. PubMed ID: 37060915
[TBL] [Abstract][Full Text] [Related]
7. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
[TBL] [Abstract][Full Text] [Related]
8. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group
Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Child Adolesc Health; 2024 Mar; 8(3):190-200. PubMed ID: 38272046
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
14. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
15. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Butler CC; Yu LM; Dorward J; Gbinigie O; Hayward G; Saville BR; Van Hecke O; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Djukanovic R; Gadola S; Kirkpatrick J; de Lusignan S; Ogburn E; Evans PH; Thomas NPB; Patel MG; Hobbs FDR;
Lancet Respir Med; 2021 Sep; 9(9):1010-1020. PubMed ID: 34329624
[TBL] [Abstract][Full Text] [Related]
17. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
18. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Yu LM; Bafadhel M; Dorward J; Hayward G; Saville BR; Gbinigie O; Van Hecke O; Ogburn E; Evans PH; Thomas NPB; Patel MG; Richards D; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Shanyinde M; de Lusignan S; Andersson MI; Barnes PJ; Russell REK; Nicolau DV; Ramakrishnan S; Hobbs FDR; Butler CC;
Lancet; 2021 Sep; 398(10303):843-855. PubMed ID: 34388395
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
